Petros Pharmaceuticals, Inc. (PTPI)

$0.75

-0.02 (-2.19%)
Rating:
Recommendation:
-
Symbol PTPI
Price $0.75
Beta 0.000
Volume Avg. 0.93M
Market Cap 15.514M
Shares () -
52 Week Range 0.646-5.2
1y Target Est -
DCF Unlevered PTPI DCF ->
DCF Levered PTPI LDCF ->
ROE -38.49% Strong Sell
ROA -23.25% Sell
Operating Margin -
Debt / Equity 49.19% Neutral
P/E -
P/B 0.45 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PTPI news


Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.